Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
VSTM
VSTM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VSTM News
Verastem Projects $17.5 Million Net Revenue for Q4 2025
Feb 04 2026
seekingalpha
Verastem Projects $30.9M Revenue for 2025 with Key Product Developments
Feb 04 2026
Newsfilter
Oncolytics Biotech's Breakthroughs in Cancer Treatment
Jan 30 2026
PRnewswire
Oncolytics Biotech's Breakthroughs in Cancer Treatment
Jan 30 2026
Newsfilter
Verastem Discontinues RAMP 203 Trial, Shifts Focus to VS-7375
Jan 02 2026
Benzinga
TEN Holdings Inc. Raises $2.25M in Private Placement, Shares Surge 17%
Dec 30 2025
Benzinga
Verastem Discontinues RAMP 203 Clinical Trial for Treatment
Dec 29 2025
Yahoo Finance
Verastem Discontinues RAMP 203 Trial to Focus on VS-7375 Development
Dec 29 2025
Newsfilter
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
Dec 28 2025
Yahoo Finance
Red Cat Reports Disappointing Q3 Results, Alongside StubHub, WhiteFiber, and Other Major Stocks Declining in Friday's Pre-Market Trading
Nov 14 2025
Benzinga
TEM Enhances Its Leadership in Genomics with New Product Launches
Nov 14 2025
NASDAQ.COM
Putting the Pieces Together: FESM May Have a Value of $44
Nov 12 2025
NASDAQ.COM
Verastem Oncology Announces Financial Results for Q3 2025 and Shares Recent Business Developments
Nov 04 2025
Newsfilter
Top Strong Buy Stocks for October 21: NEM, AS, and Others
Oct 21 2025
NASDAQ.COM
Searching for a Leading Momentum Stock? Here's Why Verastem (VSTM) is an Excellent Option
Oct 20 2025
NASDAQ.COM
Verastem Oncology Shares New Findings from GenFleet Therapeutics' Phase 1/2 Study of GFH375 (VS-7375) for Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma in China
Oct 19 2025
Yahoo Finance
Show More News
